This bill matters because it tackles a significant challenge in drug pricing: how to pay for expensive new medications in a way that ensures government programs are getting good value for their money. Many new drugs come with high price tags but uncertain long-term effectiveness for every patient. By formalizing "pay-for-performance" models, the bill aims to reduce the financial risk for taxpayers by tying drug payments to actual patient outcomes.
If this bill becomes law, it could lead to more widespread adoption of value-based drug purchasing by Medicaid and Medicare, potentially resulting in better negotiation power for government programs, lower overall drug spending if drugs don't perform as expected, and an incentive for manufacturers to focus on drugs that truly deliver results. If it doesn't pass, the legal and regulatory ambiguities surrounding these innovative payment models would likely continue, making it harder for states and manufacturers to implement them on a broader scale, and potentially leaving taxpayers to bear the full cost of drugs regardless of their real-world effectiveness.
KEY PROVISIONS
4AI-extracted
PROVISION 01
Allows drug manufacturers to report multiple 'best price points' for a single drug when sold under a value-based purchasing arrangement to Medicaid, provided the arrangement is offered to all states.
This provides flexibility for drug companies to adjust prices based on drug performance, making it easier to integrate performance-based payments into Medicaid's pricing structure.
PROVISION 02
Modifies how Average Manufacturer Price (AMP) for Medicaid and Average Sales Price (ASP) for Medicare are calculated to account for refunds or rebates given by manufacturers when a drug fails to achieve defined outcomes in a value-based purchasing arrangement.
This ensures that government programs calculate rebates and payments based on the actual net cost of a drug under performance-based contracts, potentially saving taxpayer money.
PROVISION 03
Requires the Secretary of Health and Human Services to issue guidance to State Medicaid agencies on implementing value-based purchasing arrangements for drugs provided in inpatient hospital settings, including how multiple states can collaborate.
This provides practical direction for states to adopt these innovative payment models, especially for high-cost drugs administered in hospitals, and encourages multi-state agreements.
PROVISION 04
Creates an exception to the federal Anti-Kickback Statute for payments (such as refunds or rebates) made by a drug manufacturer to a state under a value-based purchasing arrangement when a patient fails to achieve defined outcomes.
This protects manufacturers and states from legal repercussions, clearing a major hurdle for broader adoption of value-based drug payment models.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters because it tackles a significant challenge in drug pricing: how to pay for expensive new medications in a way that ensures government programs are getting good value for their money. Many new drugs come with high price tags but uncertain long-term effectiveness for every patient. By formalizing "pay-for-performance" models, the bill aims to reduce the financial risk for taxpayers by tying drug payments to actual patient outcomes.
If this bill becomes law, it could lead to more widespread adoption of value-based drug purchasing by Medicaid and Medicare, potentially resulting in better negotiation power for government programs, lower overall drug spending if drugs don't perform as expected, and an incentive for manufacturers to focus on drugs that truly deliver results. If it doesn't pass, the legal and regulatory ambiguities surrounding these innovative payment models would likely continue, making it harder for states and manufacturers to implement them on a broader scale, and potentially leaving taxpayers to bear the full cost of drugs regardless of their real-world effectiveness.
KEY PROVISIONS
AI-extracted
high
Allows drug manufacturers to report multiple 'best price points' for a single drug when sold under a value-based purchasing arrangement to Medicaid, provided the arrangement is offered to all states.
This provides flexibility for drug companies to adjust prices based on drug performance, making it easier to integrate performance-based payments into Medicaid's pricing structure.
high
Modifies how Average Manufacturer Price (AMP) for Medicaid and Average Sales Price (ASP) for Medicare are calculated to account for refunds or rebates given by manufacturers when a drug fails to achieve defined outcomes in a value-based purchasing arrangement.
This ensures that government programs calculate rebates and payments based on the actual net cost of a drug under performance-based contracts, potentially saving taxpayer money.
med
Requires the Secretary of Health and Human Services to issue guidance to State Medicaid agencies on implementing value-based purchasing arrangements for drugs provided in inpatient hospital settings, including how multiple states can collaborate.
This provides practical direction for states to adopt these innovative payment models, especially for high-cost drugs administered in hospitals, and encourages multi-state agreements.
high
Creates an exception to the federal Anti-Kickback Statute for payments (such as refunds or rebates) made by a drug manufacturer to a state under a value-based purchasing arrangement when a patient fails to achieve defined outcomes.
This protects manufacturers and states from legal repercussions, clearing a major hurdle for broader adoption of value-based drug payment models.
Not later than 180 days after the date of the enactment of this Act
Secretary of Health and Human Services to implement amendments related to the definition of Average Manufacturer Price through rulemaking.
Not later than 180 days after the date of the enactment of this Act
Secretary of Health and Human Services to issue guidance to State Medicaid agencies on value-based purchasing arrangements for inpatient drugs.
GLOSSARY
AI-written
Value-Based Purchasing Arrangement
A payment agreement where the price paid for a drug or service depends on its actual effectiveness or the health outcomes it achieves for patients.
Medicaid
A joint federal and state program that helps cover healthcare costs for people with limited income and resources.
Medicare
A federal health insurance program primarily for people aged 65 or older, certain younger people with disabilities, and individuals with End-Stage Renal Disease.
Average Manufacturer Price (AMP)
A calculation of the average price drug manufacturers receive for their outpatient drugs from wholesalers and retail pharmacies, used to determine rebates owed to Medicaid.
Average Sales Price (ASP)
A calculation of the average price drug manufacturers sell certain drugs and biologicals for, which Medicare uses to help set payment rates for those drugs.
Best Price
The lowest price a manufacturer charges for a covered outpatient drug to any wholesaler, retailer, or customer, which is used to calculate the minimum rebate owed to Medicaid.
Anti-Kickback Statute
ACTION TIMELINE
2 EVENTS
MAR 9
Introduced in House
INTROREFERRAL
MAR 9
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A federal law that prohibits knowingly and willfully offering, paying, soliciting, or receiving any money or item of value to induce or reward referrals for items or services payable by federal healthcare programs.
